Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status
AUTOR(ES)
Madrid, Manuelito A
FONTE
BioMed Central
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=549176Documentos Relacionados
- Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas
- Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
- Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
- Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status
- Gene Expression Analyses of HER-2/neu and ESR1 in Patients with Breast Cancer